NCT05945732 2026-02-12
DESTINY Breast Respond HER2-low Europe
Daiichi Sankyo
Recruiting
Clinical Trials
11 trialsNCT06210776 2026-01-12
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Daiichi Sankyo
Recruiting
NCT06663787 2025-11-28
HER2 CR
Nagoya City University
Active not recruiting
NCT06386263 2025-10-15
HER-TEMPO
AstraZeneca
Completed
NCT06504719 2025-09-15
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Hellenic Cooperative Oncology Group
Completed
NCT06727227 2025-07-01
EXPLORE
AstraZeneca
Recruiting
NCT07030569 2025-06-22
RADIOSPHER2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
NCT06231693 2025-05-08
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
AstraZeneca
Terminated
NCT06551220 2024-12-04
HEROIC
Sun Yat-sen University
Recruiting
NCT06135194 2023-11-18
Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib
Beijing 302 Hospital
Unknown
NCT05594082 2023-04-04
Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer
Fudan University
Unknown